Exhibit 99.1 CVRx Reports Second Quarter 2025 Financial and Operating Results MINNEAPOLIS, August 4, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2025. Recent Highlights "We delivered solid second quarter results and continued to build mom ...

Table of Contents As filed with the Securities and Exchange Commission on August 4, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from__________to__________ Commission File No. 001-39356 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 W. R. BERKLEY CORPORATION Form 10-Q (Exact name of registrant as specified in its charter) (Mark one) Delaware 22-1867895 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Transition Period from to . Commission File Number 1-15202 (State or other juris ...

Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025 Af irms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million SAN FRANCISCO, August 4, 2025 – Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), t ...

Exhibit 99.1 CVG REPORTS SECOND QUARTER 2025 RESULTS Second quarter sales of $172 million, EPS of $(0.12), Adjusted EBITDA of $5.2 million Continued strong free cash flow generation Updates full year 2025 guidance NEW ALBANY, OHIO (August 4, 2025) - CVG (NASDAQ: CVGI), a diversified industrial products and services company, today announced financial results for its second quarter ended June 30, 2025. Second Quarter 2025 Highlights (Results from Continuing Operations; compared with prior year, where comparis ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 95008 51 E Campbell Ave Suite 107-D Campbell, CA (Address of principal executive offices) (Zip Code) (877) 774-4211 For the transition period from ___ to ___ Commission File Number: 0 ...

收入和利润（同比环比） - 公司第二季度总收入同比增长22%至8570万美元[6] - 平台收入同比增长21%至8410万美元[6] - 公司2025年第二季度平台收入为8414.6万美元，同比增长20.9%（2024年同期为6960万美元）[32] - 公司2025年上半年净收入为338.6万美元，较2024年同期的337.3万美元基本持平[32] - 平均每单位收入（ARPU）同比增长12%至约955美元[6] - 美元净收入留存率（NRR）为114%[6] - 非GAAP运营收入为1310万美元，占总收入的15%，去年同期为760万美元（占比11%）[6] - 非GAAP运营利润在2025年第二季度为1309万美元，同比增长72%[38] - 非GAAP净利润在2025年第二季度为1307.4万美元，同比增长42.7%[40] - 完全稀释后非GAAP每股收益在2025年第二季度为0.07美元，同比增长40%[40] - 公司2025年第二季度每股基本收益为0.01美元，较2024年同期的0.04美元下降75%[32] 成本和费用（同比环比） - 公司2025年第二季度研发费用为1761.4万美元，占营收比例20.5%（2024年同期为1695.7万美元）[32] - 研发GAAP支出在2025年第二季度为1761.4万美元，同比增长3.9%[36] - 销售与营销GAAP支出在2025年第二季度为1290.3万美元，同比下降3%[36] - 一般及行政GAAP支出在2025年第二季度为1611.7万美元，同比增长86%[38] - 公司2025年上半年股票薪酬支出为1867.5万美元，较2024年同期的2125.6万美元下降12.1%[34] 毛利润（同比环比） - 毛利润同比增长10%至4390万美元，占总收入的51%[6] - 非GAAP毛利润同比增长10%至4880万美元，占总收入的57%[6] - 平台GAAP毛利润在2025年第二季度为4374.7万美元，同比增长9.9%[36] - 平台非GAAP毛利润在2025年第二季度为4852.2万美元，同比增长9.9%[36] - 总GAAP毛利润率从2024年第二季度的57%下降至2025年第二季度的51%[36] 现金流和投资 - 非GAAP自由现金流在2025年第二季度为2403万美元，同比增长69.8%[42] - 公司2025年上半年经营活动现金流为2738.6万美元，较2024年同期的2415.8万美元增长13.4%[34] - 现金及短期/长期投资总额为4.285亿美元（截至2025年6月30日）[6] - 公司现金及现金等价物从2024年12月31日的2.867亿美元增长至2025年6月30日的3.093亿美元，增幅7.9%[30] - 公司短期投资从2024年底的7397.8万美元降至2025年6月的6811.1万美元，降幅7.9%[30] 业务表现 - 活跃门店数量同比增长9%至约8.9万家，较上一季度增加约1000家[6] 公司资产和股权 - 公司总资产从2024年底的7.5476亿美元增至2025年6月的7.8067亿美元，增幅3.4%[30] - 公司2025年6月流通股总数较2024年12月增加470万股（A类+B类合计）[30] - 公司将以20亿美元股权价值被Thoma Bravo收购，每股现金对价10.25美元，较4月30日股价溢价65%[4]

EXHIBIT 99.1 SITIO ROYALTIES REPORTS SECOND QUARTER 2025 OPERATIONAL AND FINANCIAL RESULTS DENVER, Colorado — August 4, 2025 — Sitio Royalties Corp. (NYSE: STR) ("Sitio", "STR" or the "Company") today announced second quarter 2025 operational and financial results. Unless the context clearly indicates otherwise, references to "we", "our", "us" or similar terms refer to Sitio and its subsidiaries. For the second quarter of 2025, consolidated net income was $14.5 million and Adjusted EBITDA was $125.4 million ...

Exhibit 99.1 Ichor Holdings, Ltd. Announces Second Quarter 2025 Financial Results FREMONT, Calif., August 4, 2025–Ichor Holdings, Ltd. (NASDAQ: ICHR), a leader in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment, today announced second quarter 2025 financial results. Second quarter 2025 highlights: "Within a relatively steady customer demand environment year-to-date, we continue to make progress driving the expansion of our p ...

Washington D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 0-25837 HEIDRICK & STRUGGLES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION (State or Other Jurisdic ...